Literature DB >> 25651787

Global cancer statistics, 2012.

Lindsey A Torre1, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal.   

Abstract

Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide. Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide. Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries. Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males. In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death. Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries. This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment. Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer). A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.
© 2015 American Cancer Society.

Entities:  

Keywords:  cancer; epidemiology; health disparities; incidence; survival

Mesh:

Year:  2015        PMID: 25651787     DOI: 10.3322/caac.21262

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.

Authors:  Kenji Zennami; Su Mi Choi; Ross Liao; Ying Li; Wikum Dinalankara; Luigi Marchionni; Fatema H Rafiqi; Akira Kurozumi; Koji Hatano; Shawn E Lupold
Journal:  Mol Cancer Res       Date:  2018-12-05       Impact factor: 5.852

2.  Overexpression and biological function of MEF2D in human pancreatic cancer.

Authors:  Zhiwang Song; Chan Feng; Yonglin Lu; Yong Gao; Yun Lin; Chunyan Dong
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

3.  The long noncoding RNA LINC00473, a target of microRNA 34a, promotes tumorigenesis by inhibiting ILF2 degradation in cervical cancer.

Authors:  Can Shi; Yijun Yang; Juanpeng Yu; Fei Meng; Ting Zhang; Yingchun Gao
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

4.  Expression of miR-149-3p inhibits proliferation, migration, and invasion of bladder cancer by targeting S100A4.

Authors:  Dengke Yang; Guang Du; An Xu; Xuetao Xi; Dong Li
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

5.  Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance.

Authors:  Lin Yang; Adam S Kibel; Graham A Colditz; Ratna Pakpahan; Kellie R Imm; Sonya Izadi; Robert L Grubb; Kathleen Y Wolin; Siobhan Sutcliffe
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

6.  Construction and analysis of circular RNA molecular regulatory networks in liver cancer.

Authors:  Shuangchun Ren; Zhuoyuan Xin; Yinyan Xu; Jianting Xu; Guoqing Wang
Journal:  Cell Cycle       Date:  2017-11-03       Impact factor: 4.534

7.  Expansion of patient-derived circulating tumor cells from liquid biopsies using a CTC microfluidic culture device.

Authors:  Bee Luan Khoo; Gianluca Grenci; Ying Bena Lim; Soo Chin Lee; Jongyoon Han; Chwee Teck Lim
Journal:  Nat Protoc       Date:  2017-12-07       Impact factor: 13.491

8.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

9.  Effects of exercise on the quality of life in breast cancer patients: a systematic review of randomized controlled trials.

Authors:  Xinyan Zhang; Yuxiang Li; Dongling Liu
Journal:  Support Care Cancer       Date:  2018-07-21       Impact factor: 3.603

10.  KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase.

Authors:  Xuejun Yang; Dongmei Zhang; Sha Liu; Xiaojie Li; Wanglai Hu; Chuanchun Han
Journal:  Am J Cancer Res       Date:  2018-06-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.